GlassScriptPhysician profile
Naveen V Kumar
NPI 1306038450
$5,114.04
in general payments reported to CMS, 2019-2025
21 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what 89% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
See the full distribution for Otolaryngology/Facial Plastic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $90.54 · 2021: $1,016 · 2022: $936 · 2023: $884 · 2024: $444 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,763 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,763.03 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,572.93 | 2021-2025 | Inspire |
| Stryker Corporation | $813.41 | 2019-2025 | Clarifix, Medline Industries, INC., Audion Et Dilation System |
| Optinose US, INC. | $714.12 | 2019-2025 | |
| Glaxosmithkline, LLC. | $672.98 | 2021-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $275.70 | 2019-2025 | Dupixent |
| Genzyme Corporation | $272.65 | 2021-2025 | |
| Karl Storz Endoscopy-America | $210.27 | 2019-2021 | |
| Neurent Medical Limited | $121.29 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Sanofi-Aventis U.S. LLC | $98.99 | 2025 | |
| Davol INC. | $72.79 | 2020-2022 | |
| Smith+Nephew, INC. | $50.25 | 2019-2022 | |
| Aerin Medical INC. | $48.77 | 2019-2025 | |
| Intersect Ent, INC. | $40.24 | 2019-2020 | |
| Amgen INC. | $36.63 | 2025 | Tezspire |
| Itamar Medical INC | $23.28 | 2022-2023 | Watchpatone |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $20.11 | 2025 | Ryaltris |
| Medtronic, INC. | $15.50 | 2022 | |
| Eisai INC. | $14.88 | 2021 | |
| Biotissue Holdings INC. | $14.14 | 2021 | |
| Becton, Dickinson and Company | $13.40 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveen Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.